International Business Machines Corp (IBM) Pops 2.71% for February 17

Equities Staff |

One of the S&P 500’s big winners for Wednesday February 17 was International Business Machines Corp (IBM) as the company’s stock climbed 2.71% to $126.07 on volume of 3.49 million shares.

The stock opened at $123.71 and saw an intraday low of $123.25 and an intraday high of $126.57. All told, the day saw a per-share gain of $3.327. The stock’s average daily volume of 5.29 million and 970.11 million shares outstanding. International Business Machines Corp now has a 50-day SMA is $129.93 and 200-day SMA is $146.12, and it has a 52-week high of $176.30 and a 52-week low of $116.90.

International Business Machines Corp is an Information Technology (IT) company. It creates business value for clients and solves business problems through integrated solutions that leverage information technology & knowledge of business processes.

Based out of Armonk, NY, International Business Machines Corp has 412,775 employees and, after today’s trading, reached a market cap of $122.3 billion. The stock’s P/E Ratio is 9.1. Its P/S ratio is 1.46, P/B ratio is 9.2, and P/FCF ratio is 32.1.

For a complete fundamental analysis analysis of International Business Machines Corp, check out’s Stock Valuation Analysis report for IBM. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

CF0005, LLC dba Mesa-Marshall #1-2

MESA Resources, Inc. ("MESA") is sponsoring the development of the oil & gas well completion project "Mesa-Marshall #1-2". MESA, founded in 1992, is engaged in the acquisition, exploration and development…


Trustify provides trust and safety in both the digital and physical worlds through our vast network of on-demand Private Investigators.By removing the large retainers and high hourly rates that traditional…